Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients

被引：0

作者：

Angell, Helen ^{[1
]}

Ros, Vidalba Rocher ^{[1
]}

Standifer, Nathan ^{[2
]}

Lai, Zhongwu ^{[1
]}

Gresty, Christopher ^{[1
]}

Delord, Jean-Pierre ^{[3
]}

De Jonge, Maja ^{[4
]}

Postel-Vinay, Sophie ^{[5
]}

Italiano, Antoine ^{[6
]}

Krebs, Matthew G. ^{[7
,8
]}

Kaufman, Bella ^{[9
]}

Park, Yeon Hee ^{[10
]}

Domchek, Susan ^{[11
]}

Herbolsheimer, Pia ^{[12
]}

Hodgson, Darren ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] MedImmune, Mountain View, CA USA

[3] Inst Claudius Regaud Oncopole, Toulouse, France

[4] Erasmus MC Canc Inst, Rotterdam, Netherlands

[5] Gustave Roussy Canc Campus, Villejuif, France

[6] Inst Bergonie, Bordeaux, France

[7] Univ Manchester, Manchester, Lancs, England

[8] Christie NHS Fdn Trust, Manchester, Lancs, England

[9] Sheba Med Ctr, Ramat Gan, Israel

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[11] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[12] AstraZeneca, Gaithersburg, MD USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P257

引用

页数：2

共 50 条

[1] An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
Domchek, Susan M.
Postel-Vinay, Sophie
Bang, Yung-Jue
Park, Yeonh H.
Alexandre, Jerome
Delord, Jean-Pierre
Italiano, Antoine
You, Benoit
Bastian, Sara
Krebs, Matthew
Wang, Ding
Waqar, Saiama
Angell, Helen
Learoyd, Maria
Chang, Shao-Chun
Gresty, Christopher
Herbolsheimer, Pia
Kaufman, Bella
CANCER RESEARCH, 2018, 78 (04)
[2] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Domchek, S. M.
Postel-Vinay, S.
Im, S-A
Park, Y. Hee
Delord, J-P
Italiano, A.
Alexandre, J.
You, B.
Bastian, S.
Krebs, M. G.
Waqar, S.
Lanasa, M.
Angell, H. K.
Tang, M.
Gresty, C.
Opincar, L.
Herbolsheimer, P.
Kaufman, B.
CANCER RESEARCH, 2019, 79 (04)
[3] Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Domchek, S.
Postel-Vinay, S.
Im, S-A.
Park, Y. H.
Delord, J-P.
Italiano, A.
Alexandre, J.
You, B.
Bastian, S.
Krebs, M. G.
Wang, D.
Waqar, S.
Lanasa, M.
Angell, H. K.
Lai, Z.
Gresty, C.
Opincar, L. M.
Herbolsheimer, P.
Kaufman, B.
ANNALS OF ONCOLOGY, 2019, 30 : 477 - 477
[4] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
McCrea, Charles
Hettle, Robert
Gulati, Poonam
Taneja, Ankush
Rajora, Preety
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 1021 - 1030
[5] Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).
Meisner, Eleanor
Rollins, Rebecca
Ensor, Joe
Moran, Amber
Woodward, Amanda
Ahn, Eugene R.
Lynch, Cynthia Anne
Citrin, Dennis L.
Hansra, Damien
Aithal, Sramila S.
Ninan, Mary
Nixon, Daniel W.
Zook, Susan
Ali, Siraj Mahamed
Markman, Maurie
Alvarez, Ricardo H.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Domchek, Susan M.
Postel-Vinay, Sophie
Im, Seock-Ah
Park, Yeon Hee
Delord, Jean-Pierre
Italiano, Antoine
Alexandre, Jerome
You, Benoit
Bastian, Sara
Krebs, Matthew G.
Wang, Ding
Waqar, Saiama N.
Lanasa, Mark
Rhee, Joon
Gao, Haiyan
Rocher-Ros, Vidalba
Jones, Emma, V
Gulati, Sakshi
Coenen-Stass, Anna
Kozarewa, Iwanka
Lai, Zhongwu
Angell, Helen K.
Opincar, Laura
Herbolsheimer, Pia
Kaufman, Bella
LANCET ONCOLOGY, 2020, 21 (09): : 1155 - 1164
[7] Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial
Senkus, Elzbieta
Delaloge, Suzette
Domchek, Susan M.
Conte, Pierfranco
Im, Seock-Ah
Xu, Binghe
Armstrong, Anne
Masuda, Norikazu
Fielding, Anitra
Robson, Mark
Tung, Nadine
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 803 - 814
[8] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
Robson, Mark E.
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Tung, Nadine M.
Armstrong, Anne
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
[9] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Robson, Mark E.
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Tung, Nadine M.
Armstrong, Anne
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[10] Late Breaking Abstract An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Drew, Y.
de Jonge, M.
Hong, S. H.
Park, Y. H.
Wolfer, A.
Brown, J.
Ferguson, M.
Gore, M. E.
Alvarez, R. H.
Gresty, C.
Angell, H.
Meyer, K.
Learoyd, M.
Tang, M.
Lanasa, M.
Herbolsheimer, P.
Domchek, S. M.
GYNECOLOGIC ONCOLOGY, 2018, 149 : 246 - 247

← 1 2 3 4 5 →